RxDoctor Payments Data

Leslye Fisher, NP

Family · Indianapolis, INNPI 1073021556

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $68,599 of the $72,668 with a category attached, or 94.4%. Every reported general payment came from a single manufacturer, AbbVie. 2025 is the largest year on record at $34,677, more than ten times the $750 reported in 2021. Among family clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$72,668in general payments, 2019–2025

Across 132 payments — averaging $550.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$73K

What the payments were for

  • Speaking & faculty fees$68,59994%
  • Travel & lodging$2,2373%
  • Food & beverage$1,8333%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie132$72,668

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$72,668 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$204,468
Medicare patients
101
Services billed
28,720

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate98$132,613
QuliptaAtogepant79$114,009
UbrelvyUbrogepant71$95,060
Aimovig AutoinjectorErenumab-Aooe89$76,235
Emgality PenGalcanezumab-Gnlm82$70,202
Emgality SyringeGalcanezumab-Gnlm45$33,432
MyrbetriqMirabegron26$16,565
Pregabalin89$5,796
Carbidopa-LevodopaCarbidopa/Levodopa57$3,918
Sumatriptan Succinate87$3,818
Gabapentin78$1,874
Levetiracetam47$1,696
Sumatriptan25$1,301
Ropinirole Hcl32$1,274
Oxcarbazepine16$1,256

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy$72,668$209,069150 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,392 family providers in Indiana.

Other family in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →